'Hcv prevalence' presentation slideshows

Coinfection HIV & Viral Hepatitis HIV ?????????? XU Weimin ???

Coinfection HIV & Viral Hepatitis HIV ?????????? XU Weimin ??? Shanghai Public Health Clinical Centre ???????????. The epidemiology of HIV and viral hepatitis coinfection HIV ??????????? ????. Introduction.

730 views • 58 slides

Hepatitis C Update: key issues along the care continuum

Hepatitis C Update: key issues along the care continuum. Oluwatoyin ( Toyin ) Adeyemi, MD Director, CORE Viral hepatitis Clinic Senior director for HIV services, Cook County Health. Triple Threat 11: HIV, HCV & Opiods Dusable Museum , June 25, 2019.

1.3k views • 52 slides

Statistics & Declining HCV infections

562 views • 44 slides

Global Distribution of HCV Infection

778 views • 44 slides

The Frontier of Research Advocacy: Hepatitis C Drug Development

The Frontier of Research Advocacy: Hepatitis C Drug Development. HIV Research Catalyst Forum Michael Carden, SUNY Downstate/Cornell Tracy Swan, Treatment Action Group. Overview. HCV & HIV/HCV: US Epi--who has it?

473 views • 36 slides

Texas Hepatitis C Initiative

Texas Hepatitis C Initiative. National Hepatitis Coordinators Conference San Antonio, TX January 2003 Gary Heseltine MD MPH Infectious Disease Epidemiology and Surveillance Division Texas Department of Health. House Bill 1652 Rep. Maxey, Danburg, Ehrhardt, Copelo, and McClendon.

320 views • 31 slides

Matt Hickman Natasha Martin, Peter Vickerman, Daniela De Angelis

The primary prevention of hepatitis C among injectors: model projections of the impact of opiate substitution therapy, needle exchange and antiviral therapy. Matt Hickman Natasha Martin, Peter Vickerman, Daniela De Angelis. Primary Prevention of HCV. Epidemiology Intervention Effectiveness

506 views • 30 slides

HCV Genotype 4 in EAST AFRICA

HCV Genotype 4 in EAST AFRICA. Francis Ssali Site Investigator, Joint Clinical Research Centre, Kampala, Uganda. General population HCV prevalence by country and region in Sub-Sahara Africa. This data was based on small studies, with mostly screening data of limited reliability.

389 views • 28 slides

Epidemiology and prevention of HCV in IDUs

402 views • 25 slides

Reducing HIV and HCV Transmission among Injecting Drug Users in New York

Reducing HIV and HCV Transmission among Injecting Drug Users in New York. Don C Des Jarlais, Holly Hagan, Courtney McKnight, Kamyar Arasteh, Samuel Friedman Beth Israel Medical Center and National Development and Research Institutes New York City. METHODS Risk Factors Study.

289 views • 21 slides

Injecting drug use and blood borne virus transmission in Wales: building the evidence base

Injecting drug use and blood borne virus transmission in Wales: building the evidence base. Project team. ICDS Dr Marion Lyons Dr Noel Craine Dr Mark Walker Josie Smith Zoe Couzens HPA Dr John Parry & Tamara Mcdonald Imperial College Dr Mathew Hickman Cardiff University Dr Barry Nix.

319 views • 21 slides

Towards adequate and non-discriminative HCV policies and services for drug users in Central and Eastern Europe

346 views • 19 slides

HCV genotype and HBV co-infection associate with HCV clearance in HIV-positive subjects

HCV genotype and HBV co-infection associate with HCV clearance in HIV-positive subjects . Yuan Dong , Chao Qiu, Xueshan Xia, Jing Wang, Haiyan Zhang, Yongheng Wang, Xiaoyan Zhang, Jianqing Xu

374 views • 18 slides

Module 3: HCV prevalence and course of HCV infection

Module 3: HCV prevalence and course of HCV infection. Module 3: HCV prevalence and course of HCV infection. Module goal To provide an overview of global and regional HCV prevalence and the natural course of infection Learning objectives

302 views • 18 slides

Norah Palmateer, Sharon Hutchinson, Avril Taylor, Elizabeth Allen, Syed Ahmed and David Goldberg

Trends in injecting risk behaviour and HCV prevalence among injecting drug users in Glasgow, 1999-2007. Norah Palmateer, Sharon Hutchinson, Avril Taylor, Elizabeth Allen, Syed Ahmed and David Goldberg. SDF Seminar, 27 th March 2009. Overview. Why Glasgow Historical HCV data

269 views • 16 slides

HIV, HCV, and HBV in injecting drug users in Europe

EMCDDA conference. May 2009. HIV, HCV, and HBV in injecting drug users in Europe. Mirjam Kretzschmar Centre for Infectious Disease Control, RIVM, and Julius Center for Health Sciences & Primary Care University Medical Centre Utrecht, The Netherlands.

301 views • 16 slides

Background

107 views • 1 slides